Atopic dermatitis and skin diseaseMental health comorbidity in patients with atopic dermatitis
Section snippets
Data source
We used data from the 2007 National Survey of Children's Health of 91,642 households, which was designed to estimate the prevalence of various child health issues, including physical, emotional, and behavioral factors. The 2007 National Survey of Children's Health was sponsored by the Maternal and Child Health Bureau and the US Department of Health and Human Services. The National Center for Health Statistics conducted a total of 91,642 interviews by using the State and Local Area Integrated
Results
Overall, 91,642 children were represented in the survey. Of these, 79,667 had seen a provider in the previous year and were included in the analyses. Characteristics of the overall population and the AD population are shown in Table I. The prevalence of the classic atopic comorbidities asthma, hay fever, and food allergy were all increased in the AD population compared with the non-AD population, as would be expected. The overall 12-month period prevalence of AD for 2007 was 12.98% (12.43% to
Discussion
Our study examining data from the 2007 National Survey of Children's Health found strong associations between AD and several mental health disorders in the US pediatric population. These data represent the first comprehensive evaluation of the mental health burden associated with pediatric AD in the United States. We found that children with AD have an increased prevalence of ADHD, depression, anxiety, conduct disorder, and autism compared with their unaffected peers. The probability of having
References (37)
- et al.
Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health
J Invest Dermatol
(2011) - et al.
The prevalence of atopic dermatitis in Oregon schoolchildren
J Am Acad Dermatol
(2000) - et al.
ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three
J Allergy Clin Immunol
(2009) - et al.
Cost of atopic dermatitis and eczema in the United States
J Am Acad Dermatol
(2002) - et al.
Atopic dermatitis in children: who cares? Who pays?
J Am Acad Dermatol
(1993) - et al.
Immune allergic response in Asperger syndrome
J Neuroimmunol
(2009) Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder
Child Adolesc Psychiatr Clin N Am
(2000)- et al.
Vulnerability factors among children at risk for anxiety disorders
Biol Psychiatry
(1999) - et al.
Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial
Brain Behav Immun
(2011) - et al.
Cerebrospinal fluid and serum markers of inflammation in autism
Pediatr Neurol
(2005)
The burden of atopic dermatitis: impact on the patient, family, and society
Pediatr Dermatol
Quality of life and disease severity are correlated in children with atopic dermatitis
Br J Dermatol
A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases
Br J Dermatol
Atopic eczema: its impact on the family and financial cost
Arch Dis Child
Comorbidities in atopic dermatitis
Curr Dermatol Rep
The psychosocial burden of childhood atopic dermatitis
Dermatol Ther
Psychological disturbance in atopic eczema: the extent of the problem in school-aged children
Br J Dermatol
Effects of atopic dermatitis on young American children and their families
Pediatrics
Cited by (339)
Financial and treatment access burden associated with atopic dermatitis comorbidities
2024, Annals of Allergy, Asthma and ImmunologyCognitive Function and Academic Achievement in Children with Early Childhood Atopic Dermatitis
2024, Journal of Investigative DermatologyPsychosocial Impacts of Allergic Disease
2023, Physician Assistant ClinicsAtopic Dermatitis
2023, Primary Care - Clinics in Office PracticeAtopic dermatitis, cognitive function and psychiatric comorbidities across early childhood and adolescence in a population-based UK birth cohort
2024, British Journal of Dermatology
Supported by the National Eczema Association, a Mentored Patient-oriented Research Career Development Award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health (5K23AR057486), and the OHSU School of Medicine Bacon Award. Support was also obtained from the Oregon Clinical and Translational Research Institute (OCTRI; grant no. 5 KL2 RR024141-04) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research.
Disclosure of potential conflict of interest: E. L. Simpson has received grants from the National Eczema Association, the National Institutes of Health, the Oregon Health and Science University School of Medicine Bacon Award, the Oregon Clinical and Translational Research Institute, and the National Center for Research Resources and has consultant arrangements with Alcimed, Amgen, Asubio, Brickell Biotech, Celgen Corporation, Centocor, Clarion Healthcare, Galderma Laboratories, LEK Consulting, Medicis Pharmaceutical, Panmira Pharmaceuticals, Regeneron, and Versant Ventures. The rest of the authors declare that they have no relevant conflicts of interest.